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Summary 
CD34 § cells in human cord blood and marrow are known to give rise to dendritic cells (DC), 
as well as to other myeloid lineages.  CD34 § cells are rare in adult blood, however, making it 
difficult to use CD34 + ceils to ascertain if DC progenitors  are present in the circulation  and 
if blood can be a starting point to obtain large numbers of these immunostimulatory  antigen- 
presenting cells for clinical studies. A systematic search for DC progenitors was therefore carried 
out in several contexts. In each case, we looked initially for the distinctive proliferating aggregates 
that were described previously in mice. In cord blood, it was only necessary to deplete erythroid 
progenitors, and add granulocyte/macrophage colony-stimulating factor (GM-CSF) together with 
tumor necrosis factor (TNF),  to observe many aggregates  and the production  of typical DC 
progeny. In adult blood from patients receiving CSFs after chemotherapy for malignancy,  GM- 
CSF and TNF likewise generated characteristic  DCs from HLA-DR negative precursors.  However, 
in adult blood from healthy donors, the above approaches only generated small DC aggregates 
which then seemed to become monocytes. When interleukin 4 was used to suppress monocyte 
development  (Jansen, J.  H.,  G.-J.  H.  M.  Wientjens,  W.  E.  Fibbe, K.  Willemze,  and H.  C. 
Kluin-Nelemans.  1989. J. Exp. Med.  170:577.),  the addition of GM-CSF led to the formation 
of large proliferating DC aggregates and within 5-7 d, many nonproliferating progeny, about 
3-8 million cells per 40 ml of blood. The progeny had a characteristic morphology and surface 
composition (e.g., abundant HLA-DK and accessory molecules for cell-mediated immunity) and 
were potent stimulators of quiescent T cells. Therefore, large numbers of DCs can be mobilized 
by specific cytokines from progenitors in the blood stream.  These relatively large numbers of 
DC progeny should facilitate future  studies of their FceRI and CD4 receptors,  and their use 
in  stimulating  T  cell-mediated resistance  to viruses and tumors. 
D 
endritic  cells (DC) 2 provide an  effective pathway for 
presenting antigens to T cells in situ, both self-antigens 
during T cell development and foreign antigens during im- 
munity (for a review see reference 1). As such, the delinea- 
tion of developmental pathways for DCs themselves is of some 
importance.  By identifying the sites in which DC progen- 
1 S.  Gruner was  a visiting scientist from the  Charit6, Humboldt- 
University, Berlin, Germany. He died in a tragic avalanche  accident in April 
1993. 
2 Abbreviation used in this paper: DC, dendritic cell. 
83  J. Exp. Med. ￿9  The Rockefeller 
Volume 180  July 1994  83-93 
itors are found,  as well as the requisite cytokines for their 
proliferation and maturation,  one would have much better 
access to a cell type that mediates clonal deletion of autoreac- 
tive T  cells in the thymus (2) as well as clonal sensitization 
of peripheral  T  cells  (3-6). 
Two features are well described for the DC developmental 
pathway: DCs can originate from bone marrow progenitors 
(7-10),  and both the proliferation and maturation  of DCs 
are enhanced by the cytokine GM-CSF (11-21). Early detailed 
descriptions of the formation of DCs from proliferating pro- 
genitors were obtained using mouse blood (11) and shortly 
thereafter,  mouse marrow (12).  It was noted that an MHC 
class II negative precursor could be driven to form distinc- 
tive, proliferating aggregates which in turn gave rise to typ- 
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of features: irregular cell shape and motility,  abundance of 
surface molecules that  are involved in effective antigen pre- 
sentation, potent stimulation of quiescent T cells in the MLIL 
(11, 12) and mycobacterial response (22), and homing to the 
T  cell areas  of lymphoid tissues in  situ. 
Prior reports have also defined DC precursors in humans, 
primarily within the CD34 + progenitor pool in cord blood 
(14,  15) and adult marrow (16,  23). However, the applica- 
bility of this information has been somewhat limited by the 
need  to  start  with  the  trace  CD34 §  subset.  To date,  the 
reported yields of progeny also are small if one is aspiring 
to use DCs to manipulate  the immune response in autolo- 
gous human T cells. Given the capacity of DCs to elicit strong 
antigen-specific helper and killer T cell responses (1), one would 
like to identify accessible sites containing  human DC pro- 
genitors as well as pathways for their proliferative expansion. 
Since blood is the most accessible tissue for clinical studies, 
we set out to extend the findings that were reported in mouse 
blood to humans.  However, when we tried to induce DC 
growth by adding GM-CSF to human blood, we identified 
actively proliferating DC aggregates only infrequently. Rather 
than conclude that DC progenitors were present in mouse 
blood but absent from human blood, we performed a step- 
wise analysis  of the criteria and progenitor populations that 
exist in human blood in different situations.  As is described 
here, the parameters that were productive with mouse blood 
(11) were indeed applicable to humans as long as one began 
with neonatal cord blood from adults who were receiving 
CSF  replacement  after  chemotherapy.  Knowing  that  the 
criteria  could be extended from mice to humans,  we then 
returned to normal blood from healthy adults.  Conditions 
for the generation of large numbers of typical DCs from ag- 
gregates of proliferating progenitors were identified. A com- 
bination of GM-CSF and IL-4 reproducibly provides about 
3-8 million  potent  DCs from a 40-ml blood sample. 
Materials and Methods 
Culture Medium.  We used RPMI 1640 supplemented with 200 
mM L-glutamine, 50 #M 2-ME, 20/~g/ml gentamicin, and either 
5-10% FCS (56~  for 0.5 h; Seromed-Biochrom KG, Berlin, Ger- 
many) or, in some experiments  with 5% cord blood serum. 
Recombinant Human  Cytokines.  GM-CSF  (3.1  x  106 U/rag) 
was kindly provided by Dr. E. Liehl (Sandoz Research Institute, 
Vienna,  Austria);  TNF-c~ (6  x  107 U/rag) by Dr.  G. R. Adolf 
(Ernst Boehringer Institut flit Arzneimittelforschung, Vienna, Aus- 
tria); and IDlc~ (3  x  10  s U [D10 assay]/mg) by Dr. P. Lomedico 
(Hoffmann La Roche Inc., Nutley, NJ). Ib4 was commercially ob- 
tained material (107 U/mg) (Genzyme Corp., Cambridge, MA) or 
supernatant  from  IL-4 gene-transfected  COS  cells (3  x  104 
U/ml), kindly provided by Dr. G. Le Gros (Ciba-Geigy Ltd., Basel, 
Switzerland). M-CSF (1.9 x  106 U/mg) was a gift of Dr. S. Clark 
(Genetics Institute,  Cambridge,  MA). IL-3 and G-CSF were pur- 
chased from Genzyme Corp. 
mAbs.  We used the following mouse mAbs (see reference 24 
uuless defined here): W6/32,  anti-HLA-A,B,C (HB95 from the 
American Type Culture Collection, [ATCC] Rockville, MD); L243, 
anti-HLA-DR (Becton Dickinson  & Co. [BD], Mountain  View, 
CA); 9.3F10, anti-HLA-DR+DQ (HB180 from ATCC); RFD1, 
anti-HLA-DQ-related (gift of L. W. Poulter, Royal Free Hospital, 
London,  England);  B7/21,  anti-HLA-DP  (BD); UCHbl, anti- 
CD45RO (Dako Corp., Glostmp, Denmark); 4G10, anti-CD45RA; 
3C10 and LeuM3 (BD), anti-CD14;  EBM11, anti-CD68  (Dako); 
LeuM1, anti-CD15 (BD); LeuM9, anti-CD33 (BD); HPCA-1, anti- 
CD34 (BD); Leullb, anti-CD16 (BD); 2A3, anti-CD25 (BD); IV.3 
(M. Fanger, Dartmouth College Medical School, Hanover, NH) 
and CIKM5 (G. Pilkington, MacCallum Hospital, Melbourne, Aus- 
tralia), anti-FcyRII/CD32; 15-1, anti-FceRI (J.-P. Kinet, National 
Institute  of Allergy and Infectious Diseases, National Institutes of 
Health,  RockviUe, MD [25]); OKT-6,  anti-CDla (Ortho Phar- 
maceuticals, Raritan,  NJ); Leu4 (BD) and OKT-3 (Ortho), anti- 
CD3; Leu3a+b, anti-CD4 (BD); Leul, anti-CD5  (BD); Leu2a, 
anti-CD8 (BD); Leu12, anti-CD19 (BE)); Leu16, anti-CD20 (BD); 
VIB-E3, anti-CD24  (W. Knapp,  University  of Vienna, Vienna, 
Austria); G28-5, anti-CD40 (J. A. Ledbetter, Bristol-Myers Squibb 
Pharmaceutical Research Institute,  Seattle, WA); TB133, anti-leu- 
kocyte function-associated  antigen 1 (LFA-1)/CD11a and CLB54, 
anti-CD18 (both from S. T. Pals, Free University, Amsterdam, The 
Netherlands);  LeuMS, anti-CD11c  (BD);  7F7, anti-intercellular 
adhesion molecule 1 (ICAM-1)/CD54 (M. P. Dierich, University 
of Innsbruck,  Innsbruck,  Austria); AICD58, anti-LFA-3/CD58 
(Immunotech, Marseille, France); BB1, anti-B7/BB1/CD80 (E. A. 
Clark, University of Washington, Seattle, WA); Lag, anti-Birbeck- 
granule-associated (M. Kashihara-Sawami, Kyoto University, Kyoto, 
Japan [26]); VIE-G4,  antiglycophorin  (O. Majdic, University of 
Vienna); and Ki-67, proliferation-associated antigen (Dako [27]). 
Culture of DC from Cord Blood.  Cord blood was collected ac- 
cording to institutional  guidelines during normal full-term deliv- 
eries. PBMC were isolated by flotation on Lymphoprep (Nycomed, 
Oslo, Norway), washed, incubated once in saturating  concentra- 
tions  of  antiglycophorin  mAb  anti-HLA-DK  and  anti-CD3, 
washed, panned (10 min on ice, then 20 min at room temperature) 
twice onto bacterial petri dishes coated with goat anti-mouse Ig 
(H+L) Ab (Jackson ImmunoResearch  Laboratories, West Grove, 
PA). The nonadherent fractions were then plated in 24-weU  dishes 
(Costar Corp.,  Cambridge,  MA) and cultured as described in de- 
tail in Results. 
Culture of  DCs  from the Blood of Cancer  Patients.  Peripheral blood 
was obtained with the informed consent of cancer patients in com- 
plete remission during hematopoietic recovery after high-dose con- 
solidation chemotherapy and subcutaneous daily administration of 
G-CSF (300 gg human rG-CSF [Neupogen; Hoffmann-LaRoche, 
Basel, Switzerland] to 15 patients with leukemias/lymphomas, and 
to two patients  with solid tumors,  or GM-CSF (400 gg human 
rGM-CSF [Leukomax; Sandoz, Basel, Switzerland] to one patient 
with leukemia and two patients with solid tumors.  PBMC were 
prepared by sedimentation in Lymphoprep, coated with anti-HLA- 
DR plus anti-CD3  mAbs, washed, and panned twice as described 
above. Nonadherent,  depleted fractions were then processed ac- 
cording  to the protocol  described in detail in Results. 
Culture of DC from the Blood of Healthy Adults.  PBMC were 
obtained from either 40-100 ml heparinized fresh whole blood or 
leukocyte-enriched buffy coats (28), and processed as described in 
detail in Results. 
PhenotypicAnalysis.  We per formed phenotypic analysis exactly 
as described previously (29) by immunolabeling  and flow cytom- 
etry analysis, and by immunoperoxidase/immunofluorescence  on 
cells cytospun or attached by poly-t-lysine to glass slides. 
T Cell Stimulation Assays.  Allogeneic primary MLR and ox- 
idative mitogenesis were performed exactly as described (29). 
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We systematically evaluated three different situations  to 
generate DCs from proliferating progenitors in blood. Our 
goals were to define requisite criteria and cytokines for prolifer- 
ating DCs, but at the same time to avoid the need to enrich 
for  CD34 +  progenitor  populations  which are  so  few in 
number. 
Cord Blood Mononuclear  Cells  as a Source for DC Progen- 
itors.  We began with cord blood, since a prior report had 
shown that 0.5-106 enriched (>95%)  CD34 + cord blood 
cells could give rise to 1-2.5  x  107 DCs if cultured for 14 
d in a combination of GM-CSF and TNF (14). A limitation 
to this previous protocol was that cord blood only contains 
0.9-2.6% CD34 § cells (30). Therefore, we assessed a prior 
technique with adult mouse blood (11) in which unfractio- 
hated cells or MHC class II negative cells, were cultured in 
GM-CSF. We found that the varying,  yet substantial  per- 
centage of  nucleated erythroid cells in human cord blood was 
toxic and that these could be removed by panning with an- 
tiglycophorin A  mAb.  We began,  then with  erythroid- 
depleted cord blood cells with a low buoyant density (<~1.077 
g/ml) and plated these at 1-2  x  106/ml in 1 ml of standard 
medium supplemented with GM-CSF  (400-800  U/ml)  + 
TNF  (50 U/ml).  The wells were fed every other day by 
aspirating 0.3 ml medium and adding back 0.5 ml medium 
with cytokines. 
The subsequent events were similar to those described pre- 
viously with mouse blood. First, small adherent aggregates 
appeared after 4-7 d (Fig. 1, A and B). Many of the periph- 
eral cells displayed a veiled or dendritic appearance, and these 
adhered loosely to a nest of spindle-shaped cells. Nonadherent 
cells could be removed by careful rinsing in warm medium, 
but this was not essential. The adherent aggregates enlarged 
over the next 7-10 d, indicating proliferative activity (Fig. 
1 C).  Typical "veiled" DCs  (Fig.  1,  D  and E) were then 
released. These DC aggregates only developed if GM-CSF 
was added to the medium. TNF although not essential, in- 
creased aggregate size and DC yield by 50-100%.  It was ad- 
vantageous to remove the TNF during the last 1-2 d of cul- 
ture to permit the release of single, mature DCs. 
The released DCs were identified by three sets of criteria. 
First, the cells by inverted phase contrast microscopy showed 
characteristic thin motile cytoplasmic processes or veils (Fig. 
1, D and E). The typical ultrastructure of DCs was noted 
by  electron  microscopy  (see below).  Only  one  Langer- 
hans cell granule (Birbeck granule)  was found in 100 cell 
profiles. Second, the DCs had the standard phenotype i.e., 
HLA-DR rich but negative for markers of other cells, e.g., 
CD3/14/19/20. Like epidermal Langerhans cells, CDla was 
detected but only 1-2% of the cells reacted with an antigen 
associated with Langerhans cell granules (anti-Lag) (26). It 
Figure  1.  Development of DCs in liquid cultures of cord blood mononudear cells supplemented with GM-CSF and TNF. After 6 d, small adherent 
aggregates are visible under the inverted phase contrast microscope (A). Higher magnification reveals that they display typical veils at their edges (white 
arrows), and are af~xed to adherent spindle-shaped cells (B). At day 14, the DC aggregates have become much larger (C), and then finally release typical 
single DCs which display many processes (D, bright field), notably characteristic veils (arrow  indicates one such veil that appears en face) (E, phase 
contrast).  (A and C)  x25;  (B)  xl00;  (D and E)  x350. 
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Figure 2.  T cell stimulatory function (primary allogeneic MLR) of dendritic cells (DC) grown from cord blood with GM-CSF plus TNF-ot (A), 
DC grown with GM-CSF plus TNF from the blood of cancer patients after high-dose chemotherapy and G-CSF treatment (/3), and DC grown from 
normal peripheral blood with GM-CSF plus TNF-ot (C), or with GM-CSF plus II.,4 (D-F). Responder cells were purified T lymphocytes (2  x  105 
in 96 flat bottom wells). Equal numbers of irradiated (3,000 rad, 137Cs) blood DC (0, all panels) as identified by FACS  |  analyses (CDla §  + 
cells, compare with Fig. 5) were compared both with cultured epidermal Langerhans cells (LC) from the same donor in D and with poorly stimulating 
cell populations (whole PBMC in D and E; adherent macrophages from the same cultures in C; and control cultures grown in the absence of cytokines 
in F [A]). Note that DC are 10-50-fold stronger than PBMC (D and E) or macrophages  (C) and that they are comparable with DC from skin (D). 
In addition, B and E  show the enhancing effect of II.-1 (added during the last 24 h of culture) on the T cell stimulatory capacity of DCs. Without 
cytokines,  no immunostimulatory DCs develop in the cultures (F). 
is interesting  to note that  these were in the center of rare 
residual aggregates. Third, the cord blood-derived DCs were 
potent  stimulators  of resting  T  cells  in the primary MLR 
(Fig. 2 A) as well as oxidative mitogenesis (data not shown). 
The inclusion of TNF in the culture medium increased the 
immunostimulatory  function  of the DCs  (Fig.  2 A). 
The above protocol has  proven reproducible in 21  stan- 
dardized  experiments  and generates  1-5  x  106 DCs  from 
40 ml of cord blood at a purity of 20-50% (Table 1). Purity 
can be increased to >80% by flotation on metrizamide (28) 
columns. We conclude that (a) it is not necessary to enrich 
for CD34 + precursors  to  generate  typical DCs  from cord 
Table  1.  DC Progenitors in Human Blood 
Enrichment  of DC  Time of  DC  yields/  Percent DC  Cytokines 
Type of blood donor  progenitors  culture  40  ml blood  enrichment  added 
d  % 
Neonatal,  cord blood  Remove  glycophorin +  10-20  1-5  ￿  106  20-50  GM-CSF 
erythroid cells  TNF-ot 
Adult blood,  patients,  Remove  CD3 §  and  16  4-8  x  106  60-80  GM-CSF 
chemotherapy,  and  HLA-DR + cells  TNF-cr 
CSF  therapy 
Adult blood,  normal  Bulk  PBMC,  5-7  3-8  ￿  106  40-80  GM-CSF 
adherent  and  IL-4 
loosely adherent 
86  Proliferating Dendritic Cell Progenitors in Human Blood blood, and (b) the criteria that proved useful in identifying 
aggregates of proliferating progenitors in mouse blood are 
also  applicable to  human cells. 
DC Progenitors  in the Blood of Cancer Patients  during Hema- 
topoietic  Recovery  from Chemotherapy.  We next studied blood 
mononuclear cells  from  cancer  patients  in  full  remission 
(leukemias/lymphomas and solid tumors) after high-dose che- 
motherapy and either G-CSF  (17 patients) or GM-CSF (3 
patients) treatment. It is known that in the hematopoietic 
recovery of such patients, progenitors are mobilized into the 
blood in substantial numbers (0.5-6.0%  CD34 + cells) (31, 
32).  Instead of enriching for CD34 + cells,  we simply re- 
moved CD3 + and DR + cells by panning,  and then plated 
1-2  x  106 cells in 1 ml of medium with 5-10%  FCS or 5% 
cord serum plus 400-800 U/ml GM-CSF. The nonadherent 
cells were transferred at day 2  (or in  some experiments at 
day 1) and cultured for  16-d  feeding every other day. 
Growing DC aggregates appeared on day 3-5 and expanded 
in size until day 11 (data not shown, but compare with Fig. 
3). The aggregates developed peripheral veils and initially were 
loosely attached to a stroma but later were nonadherent. The 
wells were subcultured, e.g., one well split  to two to three 
wells, when the cell density increased, or if more tightly ad- 
herent, smooth, non-DC clusters appeared (contaminating 
macrophage and granulocyte progenitors). When the DC ag- 
gregates became very large (day 12-16),  it was easy to dis- 
sociate the cells and float the mature DCs on metrizamide 
columns. 
The DCs that developed in this manner had a typical mot- 
phology by light and electron microscopy (data not shown, 
but comparable to Figs.  3 and 6). The phenotype was again 
MHC  class  II  rich but  null  for CD3/14/19/20  (data not 
shown). MLR stimulatory function was potent (Fig.  2 B). 
In contrast to cord blood-derived DCs,  CDla and Lag an- 
tigens were not  seen (data not  shown). 
GM-CSF proved essential for DC development. G-CSF, 
M-CSF,  and IL-3 were inactive. Exposure to  3,000  tad of 
ionizing irradiation blocked DC development. Addition of 
TNF at 10-50 U/ml usually, though not always,  increased 
DC yields up to twofold, and always improved the function 
of DCs (Fig. 2 B). Human rlL-1 (50 LAF U/ml), when added 
during the last 24 h in some experiments, further increased 
function (Fig.  2 B). 
Starting from 40 ml blood, and using both GM-CSF and 
TNF, the yield (Table 1) of mature DCs was 4-8  x  106 at 
16 d with 60-80% purity. This is at least 20 times the yield 
of mature DCs  in fresh normal blood  (28,  33). 
Proliferating  DC Aggregates  from Normal  Adult Blood.  When 
we applied the above methods to blood from healthy adults, 
we did observe some small, adherent, veiled aggregates be- 
tween days 8 and 16.  In all 20 experiments, the aggregates 
then deteriorated and did not enlarge, leaving behind non- 
viable cells or less often, a few macrophages.  Because a stromal 
monolayer was not evident in the cultures, we next omitted 
the panning step with anti-CD3 and HLA-DR in case the 
panning  antibodies  removed required  accessory cells.  We 
simply plated 106 bulk mononuclear cells in 1 ml of medium 
with GM-CSF (800  U/ml) and TNF (50 U/ml), and after 
Figure 3.  Development  of DCs in liquid cultures of normal, adult blood mononuclear cells supplemented with GM-CSF plus Ib4. On day 2.5, 
small adherent DC aggregates are readily visible under the inverted phase contrast microscope (tt). On day 7, the DC aggregates have become nonad- 
herent,  very large, and loose (B). The nonadherent fraction of the cultures was harvested and vigorously resuspended to obtain single DCs in large 
numbers (C, arrows mark some veils). (A and B)  x25; (C)  xS00. 
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observed the adherent cells every 12 h under the inverted mi- 
croscope. To our surprise, many small adherent aggregates 
developed within 2 d, and most were covered with typical 
DC veils. However within two more days, the aggregated 
cells became round and gave rise to a monolayer of macro- 
phages. These events took place whether GM-CSF or GM- 
CSF plus TNF were added. However, by day 12-16, typical 
expanding DC aggregates appeared  in some of the wells. These 
aggregates were loosely affixed to an adherent monolayer as 
previously observed in mouse blood (11) (data not shown). 
The DCs  that were released were typical in morphology, 
phenotype (data not shown), and T  cell stimulatory func- 
tion (Fig. 2 C). The yield was about 4% of the initial number 
of mononuclear cells plated,  which is far greater than the 
0.5-1%  yield of DCs in fresh blood (28, 33). 
We suspected from these findings that DC precursors were 
actually quite numerous in blood, but that the precursor still 
had the potential to give rise to macrophages.  The latter is 
known to be the case for the CFUs that GM-CSF  induces 
in mouse (34). Since IL-4 at 500-1,000 U/ml blocks macro- 
phage colony formation (35), we added IL-4 to GM-CSF and 
repeated the experiments. 
The combination of GM-CSF  and IL-4  produced two 
striking findings. First, the numerous, initial veiled aggregates 
(Fig. 3 A) did not transform into macrophages but rather 
increased rapidly in size over the next few days (Fig. 3 B). 
The aggregates became nonadherent, displayed typical veils 
all over the periphery, and began to release mature DCs (Fig. 
3 C). Second, the single adherent cells (presumably mono- 
cytes) that were scattered in between the small adherent ag- 
gregates, also became nonadherent and developed processes 
similar to those of typical DCs (data not shown). Growing 
DC aggregates  only formed in the presence of both GM- 
CSF and IL-4. The initial  nonadherent fraction  also devel- 
oped some aggregates but these were obscured by the excess 
of lymphocytes. 
After having made these observations in 20 experiments, 
we found it simpler to use larger 35-mm wells. The protocol 
was to plate 5-20  x  106 plain bulk mononuclear cells in 3 
ml of medium, to discard the nonadherent cells at 2 h with 
a very gentle rinse,  and to then culture the adherent cells 
in medium supplemented with GM-CSF (800 U/ml) and IL-4 
(500 U/ml). With the above gentle wash, the nonadherent 
cells did not develop DC aggregates, but with more vigorous 
washing, the aggregates mainly developed in the nonadherent 
fraction. 
The presumptive DC aggregates were verified  to be prolifer- 
ating by two criteria:  staining  of '~10%  of the cells with 
the Ki-67 mAb that identifies an antigen in cycling cells (27) 
(Fig. 4 D), and sensitivity to 3,000 rad. In contrast, the tightly 
adherent populations,  which could develop single cells with 
the appearance of DCs (see above), were nonproliferating as 
evidenced by a lack of staining with anti-Ki-67  mAb (Fig. 
4 D) and a resistance to 3,000  rad of irradiation. 
The combination of  GM-CSF and IL-4 reproducibly gives 
rise to large growing DC aggregates over a 5-7-d period. 
Figure  4.  Phenotype and proliferation characteristics  of DCs grown 
from normal blood with GM-CSF plus 1I.-4. Fluorescence pictures in each 
row represent identical microscopic fields of double-labeled cytospin prepa- 
rations. (Left) Panels are stained with anti-HLA-DR. DCs grown in GM- 
CSF and 11.-4 are strongly HLA-DR positive (A, left) but display only 
a dull spot of anti-CD68 reactivity  (right).  In contrast, control cells grown 
in parallel without cytokines (mainly macrophages)  show an inverted pat- 
tern: very low HLA-DR (B, left) but brilliant CD68 expression  (right). 
mAb Lag (C, right) identifies occasional Birbeck granule containing cells 
in the center of an HLA-DIL-expressing aggregate of DC (left). Peroxi- 
dase staining of nuclei and nucleoli with mAb Ki-67 (D) demonstrates 
that proliferation occurs predominantly in aggregates (/eft); singly dispersed 
DC derived from firmly adherent cells (see text) are not stained (rigkt). 
(A-C)  ￿  200; (D)  ￿  100. 
At that time, growth essentially ceased. The aggregates then 
could be disassembled by pipetting into DCs with a typical 
surface phenotype (Fig. 5), characteristic morphology at the 
light (Fig. 3 C) and electron microscopy levels (see Fig. 6), 
and strong T cell stimulatory function (Fig. 2, D-F). Human 
rlL-1  (50 LAF U/ml), when added during the last 24 h of 
culture,  amplified the stimulator),  function of DCs as ob- 
88  Proliferating Dendritic Cell Progenitors in Human  Blood Figure 5.  Cytofluorographic analysis of dendritic cells (DC) grown from normal peripheral  blood with GM-CSF plus ID4. Two different representa- 
tive experiments  are shown. Epidermal  Langerhans  cells (LC)  cultured for 3 d were included  in one experiment  for comparison.  Three-color  immunolabeling 
was performed. Cells were stained  with different  mouse mAbs followed  in sequence  by biotinylated  anti-mouse Ig, streptavidin-PE,  mouse Ig for blocking 
free binding sites, and FITC-conjugated anti-HLA-DR. Dead cells and lymphocytes were excluded from analysis by propidium iodide staining and 
light scatter properties, respectively.  More than 90% of the remaining cells were strongly MHC-dass II positive and constituted DC. The phenotype 
of this population is shown (shaded  curves). Isotype-matched  control antibodies are included in each histogram (bold  curves). Blood DC display  a phenotype 
typical for DCs as described and almost identical to cultured LC in direct comparison (24, 28, 29, 33). It is notable that they do not express CD14 
but have high levels of MHC molecules  (HLA-ABC, DR, DQ, and DP), adhesins (CD54, CD58, CDlla [not shown], and CDllc), and costimulatory 
molecules (CD40 and B7/CD80). They are also negative with markers for granulocytes (CD15), NK cells (CD16), B cells (CD19 [not shown] and 
CD20), and T cells (CD3 and CD8 [not shown]). Expression  of CD5 and the staining pattern of CD45RA and -RO are as described  for DCs isolated 
from fresh blood (33). 
served with murine DCs isolated from spleen or epidermis 
(18, 36). It is interesting to note that the blood-derived DCs 
expressed CDla,  CD4,  and FcdLI as is typical of epidermal 
Langerhans cells (25, 37, 38). Birbeck granules were not de- 
tectable by electron microscopy, however, and only a rare cell 
in the center of a residual DC aggregate stained with anti- 
Lag mAb  (26) (Fig. 4  C).  Anti-CD68  immunostaining  re- 
vealed a perinuclear zone of reactivity in some of the DCs 
(Fig. 4 A), a feature that differs from the strong diffuse granular 
staining  of macrophages  (Fig.  4  B). 
The yield of mature,  immunostimulatory DCs  (Table 1) 
was  6-15%  of the mononuclear cells plated.  This is many 
times greater than the number of DCs that can be identified 
in unstimulated  blood  (0.3-1%)  (28,  33).  The  above pro- 
tocol and yield (3-8  x  106 DCs/40 ml of blood) has proven 
reproducible in over 25 experiments with blood from healthy 
males and females (25-60-yr-old), using either fresh venipunc- 
ture  or burly coat  preparations. 
Discussion 
DC Progenitors in Human Blood: Identification.  These find- 
ings of necessity appear methodological in nature but in fact 
outline a pathway whereby the distinct DC  lineage can be 
induced  to proliferate and mature from precursors that  are 
relatively plentiful in human blood. The methodological caste 
of our results  reflects the difficulty inherent in identifying 
precursors and progeny in this distinctive immunostimula- 
tory pathway. DCs  are not yet known to express a lineage- 
specific surface antigen, as is the case with lymphocytes, e.g., 
89  Romani et al. Figure 6.  Ultrastructure of DCs grown form normal, adult blood mononuclear cells with GM-CSF plus IL-4. Low power view (x 4,700) shows 
three profiles of DCs. (Arrowheads)  Veils, i.e., thin cytoplasmic  processes  devoid  of organelles. (Bracket)  Area shown at higher magnification (x33,000) 
to demonstrate the characteristic abundance of mitochondria and paucity of lysosomes/phagosomes. 
CD3,  CD19, and CD20. A lack of lineage-specific markers 
is also typical of the individual human myeloid lineages, e.g., 
monocytes, neutrophils, basophils, and eosinophils. However, 
these other myeloid lineages have distinctive tinctorial prop- 
erties and distinctive CSFs, e.g.,  M-CSF  and G-CSF. DCs, 
in contrast,  are only known to respond to the multilineage 
cytokine GM-CSF (17, 18, 39), and their peculiar morphology, 
phenotype,  and function is best outlined with  a composite 
of approaches  (1). 
Given these inherent  difficulties,  we searched for criteria 
that were similar to those that had been used to identify im- 
mature DC progenitors (e.g., MHC class II negative) in mouse 
blood (11) and bone marrow  (12).  Mouse DCs  proliferate 
within a characteristic aggregate that  attaches loosely to an 
underlying stroma and is covered with large sheetlike processes 
or veils (compare Figs. I  and 3). By defining conditions that 
give rise to  such aggregates,  at  first containing  a few cells 
but growing to >10 cells in diameter, we could establish that 
proliferating  DC progenitors are readily detectable in the blood 
of all healthy adults,  and that  one could use these progen- 
itors  to  generate  relatively  large  numbers  of  typical  im- 
munostimulatory DCs within 7 d, i.e.,  3-8 million of such 
cells  per 40 ml of blood. 
The critical finding was that GM-CSF did induce the for- 
mation of many small DC progenitor aggregates in human 
blood, but that these did not proliferate further and seemed 
to become typical macrophages.  IL-4, a known inhibitor of 
macrophage  colony formation  (35),  allowed extensive DC 
growth  and  maturation  to ensue (Fig.  3). 
DC Progenitors in Human Blood: Cytokine Requirements.  To 
study the properties of DC progenitors in blood,  it is not 
necessary  to  enrich  for  CD34 +  multilineage  progenitors 
which are so rare (<0.1%)  in normal blood (40).  The need 
for exogenous cytokines may vary from one experimental sit- 
uation  to another  depending  on their endogenous produc- 
tion  (e.g.,  TNF) by cells in the culture.  However, it  is  to 
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to increase DC numbers and function, as described by Caux 
et al.  (14),  but primarily  when  one uses cord blood from 
patients who are receiving CSF therapy to compensate for 
chemotherapy. The function of TNF-ol may be to diminish 
granulocyte production (41, 42), and to enhance responsive- 
ness of an early progenitor to GM-CSF as by inducing  the 
/3 chain of the GM-CSF receptor (41, 42). With normal adult 
blood, IL-4 is the desired exogenous cytokine that is to be 
applied in combination with GM-CSF. We suspect that IL-4 
acts by suppressing the monocyte differentiation potential of 
the DC progenitor  (35). 
GM-CSF is essential to grow DCs from all sources used. 
Additional cytokines required for optimal DC growth from 
the various sources are, however, strikingly different (TNF-c~ 
versus IL-4). We suspect that this is due to the fact that the 
main DC progenitors involved differ.  In cord blood the DC 
aggregates likely derive from CD34 + cells as preliminary ex- 
periments  (Romani,  N.,  unpublished  observations)  have 
shown that  depletion of CD34 + cells from the initial  in- 
oculum virtually abolishes the formation of DC aggregates. 
This also readily explains the need to add TNF-ct which is 
known to induce responsiveness  to GM-CSF of CD34 + cells 
(41, 42). Ongoing experiments indicate that IL-4 does not 
seem to enhance DC development from precursors that arise 
in cord blood mononuclear  cells  supplemented  with  GM- 
CSF and TNF-o~ (Brang, D., unpublished observations). We 
do not yet know, however, whether IL-4 is produced endog- 
enously in such cultures. Endogenous IL-4 might suppress- 
similar to exogenously added IL-4 in adult blood cultures- 
the monocyte differentiation potential of more mature DC 
progenitors that  derive from CD34 + multilineage progen- 
itors in response to GM-CSF and TNF-a. DC developmental 
pathways in cultures of blood derived from cancer patients 
during hematopoietic recovery are presumably similar to cord 
blood. Besides CD34 + cells it is, however, likely that more 
committed precursors are also involved as the percentage of 
CD34 + cells in the CD3/HLA-DR-depleted mononuclear 
cell fraction did not strictly correlate with DC yields. In normal 
adult blood in response to GM-CSF and TNF-ol and only 
after a prolonged culture period (2 wk), some DC aggregates 
emerged probably from early, rare DC progenitors similar 
to those in cord blood or the blood of cancer patients during 
hematopoietic recovery. The main DC progenitor(s) in normal 
adult blood, however, appear(s) to be more frequent as only 
2 d of culture are needed before many DC aggregates appear 
(Fig.  3).  Prior work in mice (34)  and in humans  (16) has 
described that the multilineage colonies that are induced by 
GM-CSF in semisolid agar cultures contain  all three types 
of myeloid progeny, i.e., granulocytes,  macrophages, and DCs. 
The principal DC progenitor in normal human peripheral 
blood seems more differentiated since granulocytes do not 
develop. This committed progenitor is GM-CSF responsive, 
and likely bipotential,  developing into macrophages rather 
than DCs unless its monocyte differentiation potential is sup- 
pressed by IL-4. 
DC Progenitors in Human Blood: Clinical Relevance.  The 
larger  numbers of DCs that  are now available  should help 
characterize two other intriguing features of the DC pheno- 
type that are clear-cut in the progeny that can be reared with 
GM-CSF and IL-4 from human blood. One is the expression 
of FceRI receptors which could have a role in atopic derma- 
titis (25, 38), e.g., via the presentation of small amounts of 
antigen as IgE complexes. A second feature is the high level 
of expression of CD4, the principal receptor for HIV-1 (43). 
It also may be worthwhile to consider the use of IL-4 and 
GM-CSF, perhaps together with antigen-pulsed DC progen- 
itors (22), to enhance immune responses in situ. In any case, 
methods for the identification  and growth of DC progen- 
itors in human blood, especially normal adult human blood, 
should make it feasible to explore the immunogenic poten- 
tial of these cells in clinical situations,  such as the presenta- 
tion of antigens in resistance to infections and tumors. 
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